Zydus receives final approval from the USFDA for Sucralfate Tablets USP, 1 gram

Zydus receives final approval from USFDA for Roflumilast Tablets, 250 mcg

Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)

Zydus receives final approval from the USFDA for Azithromycin Tablets

Azithromycin Tablets USP, 500 mg had annual sales of US $20 million in the United States

Tillotts Pharma announces the launch of Octasa 1600 mg Tablets in Canada

The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.

Zydus receives final approval from the USFDA for Carbidopa and Levodopa Tablets

Carbidopa and Levodopa is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms

Zydus receives final approval from the USFDA for Acetazolamide Tablets

Acetazolamide is used to treat glaucoma

Granules India receives ANDA approval for Gabapentin Tablets

Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults

Lupin receives tentative approval from USFDA for Obeticholic Acid Tablets

Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of US $255 million in the US (IQVIA MAT December 2022).

Zydus receives final and tentative approval from USFDA for Tofacitinib Tablets

Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)

Lupin receives approval from USFDA for Brexpiprazole Tablets

Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)